Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
The partnership will capitalize on the combined capabilities of the two organizations
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated
